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pertension (PAH) patients, and this activation may have long-term negative effects on the pro-
gression of PAH. The purpose of this study was to evaluate the effects of transcatheter renal
sympathetic denervation (RSD) on the development of pulmonary arterial hypertension and
cardiac dysfunction in dogs using two-dimensional speckle tracking imaging. Twenty-two dogs
were randomly divided into three groups: control group (n Z 7), PAH group (n Z 8), and
PAH þ RSD group (n Z 7). All dogs were assessed using two-dimensional speckle tracking im-
aging. The ventricular strain, ventricular synchrony, left ventricular (LV) twist, and torsion rate
were analyzed to evaluate cardiac function. After 8 weeks, the right ventricular lateral longi-
tudinal strain and the septum longitudinal strain were reduced in the PAH group compared with
the control group (p < 0.001). However, these values were significantly restored in the
PAH þ RSD group compared with the PAH group (p < 0.01). The degree of LV and RV dyssyn-
chrony was significantly higher in the PAH group compared with the control group
(p < 0.001), but the degree of LV and RV dyssynchrony was significantly lower in the
PAH þ RSD group compared to the PAH group (p < 0.01). The LV twist was significantly restored
in the PAH þ RSD group compared to the PAH group (p < 0.01). Similarly, the rotation rate was
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Pulmonary arterial hypertension (PAH) adversely affects
morbidity and mortality by progressive pulmonary vascular
remodeling and increased right-sided cardiac pressure,
which lead to right heart failure and death [1,2]. A greater
understanding of the epidemiology, pathogenesis, and
pathophysiology of PAH has resulted in significant advances
in treatment of this condition over the past two decades.
However, these treatment options are not universally
available and are not always effective, emphasizing the
need for the development of novel therapies and thera-
peutic strategies.
Previous studies showed that the degree of severity of
chronic RV pressure overload is dependent on the degree of
pulmonary artery systolic pressure (PASP) rise. Increased RV
systolic pressure (RVSP) directly affects the RV perfor-
mance. Furthermore, RV pressure overload influences LV
geometry, which in turn impairs the LV segmental function,
synchrony and torsion [3e5]. To compensate, the
renineangiotensinealdosterone system (RAAS) is activated
in PAH patients [6e8], and this activation may have long-
term negative effects on the progression of PAH [9].
Maron et al. [10] demonstrated that aldosterone inhibition
reduces pulmonary pressure and pulmonary vascular resis-
tance without systemic hypotension in an animal model of
PAH, suggesting that modulation of the RAAS might be
useful for the treatment of PAH.
More recently, renal sympathetic denervation (RSD) has
proved to be a promising strategy in the treatment of re-
fractory systemic hypertension, heart failure, arrhythmias,
and sleep apnea. RSD has been shown to inhibit the activation
of the RAAS [11], suggesting a potential for RSD in the treat-
ment for PAH. However, the role of RSD as a novel therapeutic
strategy for PAH has not been investigated. In the present
study, we sought to examine the effect of RSD on PAH and
cardiac dysfunction in dogs using two-dimensional speckle
tracking imaging. Our data show that RSD prevented the
development of PAH and cardiac dysfunction in dogs by
suppressing the activation of the RAAS. These findings suggest
that RSD may be a novel strategy for the treatment of PAH.Materials and methods
Animal model
This study was carried out in Renmin Hospital of Wuhan
University, Wuhan, China from January 2013 to September
2013. The animal protocol was reviewed and approved by
the Animal Care and Use Committee of Renmin Hospital of
Wuhan University. The Ethics Committee at RenminHospital of Wuhan University approved the study protocol.
Twenty-two beagles of both sexes (10.0e14.0 kg in weight
and aged 9e12 months) and free of clinically evident dis-
ease were randomly divided into three groups: control
group (n Z 7), PAH group (n Z 8), and PAH þ RSD group
(n Z 7). The dogs in the control group received 0.1 mL/kg
dimethylformamide (DMF; to exclude the effect of DMF on
PAH, we used DMF as control). In the PAH group and
PAH þ RSD group, an injection of dehydromonocrotaline
(DHMC) (2.0 mL/kg) was performed via the right atrium.
(DHMC) was artificially synthesized as described by Mattocks
et al. [12]. The purity of the DHMC was determined by high-
performance liquid chromatography [13]. DHMC was dissolve
in 0.1 mL/kg DMF just before injection.
Dogs in the PAH þ RSD group underwent double renal
artery ablation before the injection of dehy-
dromonocrotaline. A 6F quadrupole radiofrequency abla-
tion catheter was introduced into each renal artery via
femoral artery (when tips of quadrupole radiofrequency
ablation catheter was introduced into each renal artery,
the four tips were expanded automatically and applied to
the wall of renal artery). Radiofrequency ablations lasting
up to 90 seconds (Power: 6W) were applied within each
renal artery.
Hemodynamic measurements
A hemostatic sheath was inserted into the left femoral ar-
tery, and artery blood pressure was measured. The PASP
and RVSP were determined by inserting a catheter with
fluid-filled force transducers into the jugular vein and
pushing the catheter through the right ventricle into the
main pulmonary artery, as previously described [14].
Conventional echocardiography
All dogs underwent a complete transthoracic echocardio-
graphic study, including two-dimensional, color flow, and
spectral Doppler using the GE vivid E9system (GE Vingmed
Ultrasound As, Horten, Norway). The routine standard
echocardiographic examination included the measurements
of the LV end-diastolic dimensions, RV end-diastolic di-
mensions, left atrium dimensions, right atrium dimensions,
and pulse wave Doppler examination of the mitral inflow.
From the mitral inflow Doppler signals, early transmitral
inflow (E) was obtained with the sample volume placed
between the tips of the mitral leaflets. Tissue Doppler
imaging-derived peak early diastolic velocities (E0) were
derived from the septal and lateral mitral annulus and
averaged for each dog; the mitral E/E0 ratio was subse-
quently calculated. The LV end-diastolic (LVEDV) and end-
systolic volumes (LVESV) were calculated from the apical
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stroke volume (SV) was calculated from the difference
between the LV end-diastolic and end-systolic volumes. The
LV ejection fraction was calculated from the stroke volume
divided by the LV end-diastolic volume [15].Two-dimensional speckle tracking imaging of the
ventricles
The ventricular strain, torsion, and untwisting rate were
analyzed by the two-dimensional speckle tracking echo-
cardiography technique using the ECHOPAC workstation,
as previously described [16,17]. For the analysis of the 2D-
STI results, all of the views were recorded at 40e60
frames/s. The RV lateral wall (RV LAT), interventricular
septum (IVS), and LV lateral wall (LV LAT) were divided
into three segments (basal, mid, and apex). In the apical
four-chamber view, the average value of the end-systolic
longitudinal strain (LS) of the RV LAT wall from three
segments was calculated as the RV LAT LS. Using the
apical four-chamber data, we calculated the average
value of the end-systolic LS for the inferoseptal wall and
used the apical long-axis view to obtain data for the
anteroseptal wall (in each case, averaging basal, mid, andFigure 1. Left (LV) and right ventricle (RV) synchrony of the thr
lating the standard deviation of the time to the peak longitudinal st
apical four-chamber view; LV twist and untwist rate of the three g
axis planes of six myocardial segments along the central axis.apical segments). The mean of these two strain mea-
surements was considered to be the IVS LS. From these
same images, the average value of the end-systolic LS for
three levels of the anterolateral wall and inferolateral
wall was considered to represent the LV LAT LS. In the
apical four-chamber view, the RV and LV were divided into
a six-segment model sharing the interventricular septum.
The time to the peak strain was calculated from the QRS
onset to the negative peak strain of each the six segments
of the LV and RV; the LV and RV synchrony were derived by
calculating the standard deviation of the time to the peak
longitudinal strain of the six segments (Figure 1). The LV
rotation in the basal or apical short-axis planes were
determined as the average angular displacements of six
myocardial segments along the central axis. A counter-
clockwise rotation (as viewed from the apex) was
considered positive; a clockwise rotation was considered
negative. The LV torsion was calculated as the maximal
difference between the apical and basal rotation curves
during systole [16,18]. That maximal difference per sec-
ond during early diastole was calculated as the LV
untwisting rate [16,18] (Figure 1). The digitally stored
echocardiographic data were analyzed by an experienced
sonographer, and all of the measurements represent an
average of 3e5 consecutive cycles.ee groups after 8 weeks: Synchrony was determined by calcu-
rain of six left ventricular and right ventricular segments in the
roups after 8 weeks: obtained from the basal and apical short-
Figure 2. After 8 weeks, serum angiotensin II level was
significantly increased in the pulmonary arterial hypertension
(PAH) group compared with the control group. However, serum
angiotensin II level in the PAH þ renal sympathetic denervation
(RSD) group was significantly decreased compared with the PAH
group.
408 W. Hu et al.Statistical analysis
The data are presented as the mean  standard deviation.
Differences among the groups were tested using a one-way
analysis of variance. A p value < 0.05 was considered sta-
tistically significant. All of the statistical analyses were
performed with SPSS statistical software (version 19.0; SPSS
Inc., Chicago, IL, USA).Figure 3. Blood pressure, right ventricle systolic pressure (RVSP
groups were detected respectively after 8 weeks: (A and B) systo
difference in the three groups; (C and D) RVSP and PASP of pulmonar
compared with the Control and PAH þ renal sympathetic denervatResults
Angiotensin II
After 8 weeks, serum Angiotensin II (Ang II) level was
significantly increased in the PAH group compared with the
control group (224.40  41.57 pg/mL vs. 131.28  34.63 pg/
mL, p < 0.001). However, serum Ang II level in the
PAH þ RSD group was significantly decreased compared
with the PAH group (136.63  43.60 pg/mL vs.
224.40  41.57 pg/mL, p < 0.001) (Figure 2).
Blood pressure, PASP, and RVSP
The systolic and diastolic arterial blood pressure had no
significant difference after 8 weeks among three groups
(p > 0.05; Figure 3). Compared with the control group,
PASP was significantly increased, NS dramatically reduced
in the PAH þ RSD group (28  7.9 mmHg vs. 45  11.2 mmHg
p < 0.001). Similarly, RVSP was significantly decreased in
the PAH þ RSD group compared with the PAH group
(25  6.8 mmHg vs. 43  8.7 mmHg, p < 0.001; Figure 3).
The effect of RSD on conventional
echocardiographic characteristics
Conventional echocardiographic images were successfully
obtained and analyzed in all dogs. The data are summarized), and pulmonary artery systolic pressure (PASP) of the three
lic (SBP) and diastolic blood pressure (DBP) had no significant
y arterial hypertension (PAH) group were increased significantly
ion (RSD) group.
Table 1 Characteristics of the routine echocardiography.
Control PAH PAH þ RSD
LVEDD (mm) 28.57  1.62 27.13  1.81 27.14  1.77
LAD (mm) 17.29  1.38 17.13  2.10 16.71  1.11
RVEDD (mm) 11.43  0.79 13.50  1.07* 12.14  0.69**
RAD (mm) 16.57  1.62 18.88  1.13* 17.57  1.13
E (cm/s) 72.29  2.56 77.25  2.60* 75.29  4.35
E0 (cm/s) 7.48  0.63 5.28  0.38* 6.26  0.69*,**
E/E0 9.70  0.68 14.68  1.02* 11.54  0.32*,**
LVEDV (mL) 23.86  2.19 19.25  1.75* 22.57  1.99**
LVESV (mL) 8.71  0.95 7.00  0.93* 8.14  0.90**
LVSV (mL) 15.14  1.57 12.25  1.16* 14.14  1.46*,**
LVEF% 63.57  2.30 63.38  2.77 63.71  2.29
Data are expressed as mean  standard deviation.
*p < 0.05 compared with control group.
**p < 0.05 compared with PAH group.
E Z mitral early diastolic filling velocity; E0 Z mitral early
diastolic annular velocity; EF Z ejection fraction; LAD Z left
atrium dimension; LVEDD Z left ventricular end-diastolic
dimension; LVEDV Z left ventricular end-diastolic volume;
LVESV Z left ventricular end-systolic volume; LVSV Z left
ventricular stroke volume; PAH Z pulmonary arterial hyper-
tension; RAD Z right atrium dimension; RSD Z renal sympa-
thetic denervation; RVEDD Z right ventricular end-diastolic
dimension.
Table 2 End-systolic longitudinal strain of the ventricles.
Control PAH PAH þ RSD
IVS LS (%) 21.40  0.99 17.02  1.00* 18.39  1.03*,**
LV LAT LS (%) 20.56  1.01 20.45  1.12 20.86  0.79
RV LAT LS (%) 20.68  0.95 16.34  1.36* 18.91  0.86*,**
Data are expressed as mean  standard deviation.
*p < 0.05 compared with control group.
**p < 0.05 compared with PAH group.
IVS LS Z interventricular septum end-systolic longitudinal
strain; LV LAT LS Z left ventricular lateral end-systolic longi-
tudinal strain; PAH Z pulmonary arterial hypertension;
RSD Z renal sympathetic denervation; RV LAT LS Z right ven-
tricular lateral end-systolic longitudinal strain.
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velocity of the mitral annulus (E0) was reduced significantly
in the PAH group compared with the control group
(p < 0.05); however, E0 was significantly restored in the
PAH þ RSD group compared with the PAH group
(6.26  0.69 cm/s vs. 5.28  0.38 cm/s, p Z 0.004). The
mitral E/ E0 ratio was higher in the PAH group compared
with the control group (p < 0.001); however, it was lower in
the PAH þ RSD group compared with the PAH group
(11.54  0.32 vs. 14.68  1.02, p < 0.001). After 8 weeks,
the LVEDV, LVESV, and LVSV were smaller in the PAH þ RSD
group compared with the PAH group
(LVEDVZ 19.25  1.75 mL vs. 22.57  1.99 mL, pZ 0.004;
LVESV Z 7.00  0.93 mL vs. 8.14  0.90 mL, p Z 0.028;
LVSV Z 12.25  1.16 mL vs. 14.14  1.46 mL, p Z 0.017);
however, the LV ejection fraction did not show significant
difference among three groups (Table 1).The effect of RSD on ventricular strain
The left ventricular and right ventricular end-systolic lon-
gitudinal strain values were analyzed by two-dimensional
speckle tracking (Table 2). After 8 weeks, the left ven-
tricular lateral longitudinal strain (LV LAT LS) did not show
significant difference between PAH þ RSD group and PAH
group (p > 0.05). The right ventricular lateral (RV LAT LS)
and the septum longitudinal strain (IVS LS) were reduced in
the PAH group compared with the control group (p < 0.05).
However, the RV LAT LS and the IVS LS were significantly
restored in the PAH þ RSD group compared with the PAH
group (RV LAT LS Z 18.91  0.93% vs. 16.34  1.36%,
respectively, p < 0.001; IVS LS Z 18.48  1.07% vs.
17.02  1.00%, respectively, p < 0.001; Table 2).The effect of RSD on ventricular synchrony
Ventricular synchrony was calculated using the total syn-
chrony index. After 8 weeks, the LV and RV dyssynchrony
were longer in the PAH þ RSD and PAH groups compared
with the control group (p < 0.001; Figure 4). However, the
LV dyssynchrony was smaller in the PAH þ RSD group
compared with the PAH group (25.45  3.87 ms vs.
40.40  2.83 ms, p < 0.001; Figure 4). The RV dyssynchrony
was also smaller in the PAH þ RSD group compared with the
PAH group (34.19  3.03 ms vs. 51.98  3.64 ms, p < 0.001;
Figure 4).
The effect of RSD on LV twist and torsion rate
After 8 weeks, the LV twist was dramatically reduced in the
PAH group compared with the control group (p < 0.001).
However, the LV twist was significantly restored in the
PAH þ RSD group compared with the PAH group
(10.48  0.78 vs. 8.46  1.06, p < 0.001; Figure 4). The
rotation rate was markedly decreased in the PAH group
compared with the control group (p < 0.001), but the
rotation rate was higher in the PAH þ RSD group compared
with the PAH group (102.14  4.60/s vs. 95.00  3.16/s,
p Z 0.004; Figure 4).
Discussion
The major findings of our study are as follows: (1) RSD
significantly prevented the development of PAH-induced
cardiac dysfunction and (2) RSD-mediated protective ef-
fects on PAH were partly through the inhibition of RAAS.
Speckle-tracking echocardiography is an angle-
independent technique for quantifying the myocardial
motion in PAH [19,20]. Previous studies used these novel
methods to evaluate the global and regional peak longitu-
dinal systolic strains of the LV and RV [21]. In this study, the
longitudinal strain of the RV free wall and IVS were reduced
in dogs in the PAH group and the PAH þ RSD group; however,
the longitudinal strain of the LV free wall was not signifi-
cantly changed. Unlike the LV, the RV does not tolerate
systemic arterial pressure because of its thinner wall and
higher compliance [22]. These findings were in agreement
with the results of Lo´pez-Candales et al. [23]. They
assessed the systolic function of the RV free wall, LV free
Figure 4. Left (LV) and right ventricle (RV) of the three groups were detected by the two-dimensional speckle tracking imaging
(2D-STI) after 8 weeks: (A and B) synchrony of LV and RV were determined respectively by calculating the standard deviation of the
time to the peak longitudinal strain of six ventricular segments in the apical four-chamber view; (C) in either the basal or apical
short-axis planes, an average of the angular displacements of six myocardial segments along the central axis was determined; (D)
maximal difference of LV torsion per second during early diastole.
410 W. Hu et al.wall and IVS using tissue Doppler imaging in PAH patients
and controls. Their data showed that the LV systolic func-
tion was similar between the PAH group and the controls,
whereas the systolic function of the RV free wall and IVS
were significantly impaired in the patients with PAH. In the
present study, although the longitudinal strain was reduced
in both the PAH group and PAH þ RSD group, the reduction
was significantly improved in the PAH þ RSD group.
Recent clinical studies imply that RV pressure overload
induces RV mechanical dyssynchrony [24]. Impairment of LV
mechanical synchrony could also be observed in the setting
of RV pressure overload. Further studies showed that acute
and chronic RV pressure overload negatively affected LV
mechanical synchrony associated with LV functional
impairment [4,5]. Consistent with the previous hypothesis,
in the present study, LV synchrony and RV synchrony were
impaired in the PAH group and the PAH þ RSD group.
However, this dysynchrony was significantly restored in the
PAH þ RSD group compared with the PAH group.
The LV twist and untwist rate are sensitive to changes in
regional and global LV dysfunction [25]. In this study, the LV
twist was decreased in the PAH and PAH þ RSD groups.
However, the decrease was significantly improved in the
PAH þ RSD group compared with the PAH group. Similarly,
the LV untwist rate was reduced more significantly in the
PAH group than the PAH þ RSD group. Dong et al. [26]
demonstrated that preload, afterload and contractility
were predictors of LV torsion on a multiple regression
analysis. Gibbons Kroeker et al. [27] evaluated the effect ofpreload, afterload, contractility, and heart rate on apical
rotation. The authors concluded that preload was a major
determinant of apical rotation. In our study, we found that
the LV end diastolic volume and end systolic volume were
significantly lower in the PAH þ RSD group than the PAH
group. Therefore, RSD exerts protective effect on the car-
diac function and ventricular synchrony in dogs with PAH.
The mechanism underlying the protective effect of RSD
on the development of PAH and cardiac dysfunction re-
mains unclear. Endothelial dysregulation is thought to be
the first step in the vascular remodeling of the pulmonary
arteries during the development of PAH [28]. The classic
RAAS is one of the causal factors of endothelial dysfunction
and vascular remodeling in the development of PAH [29]. In
the traditional view, the RAAS is composed of mainly
angiotensin-converting enzyme, Ang II, and Ang I type 1
receptor. Ang II adversely affects pulmonary vasoconstric-
tion and vascular remodeling, contributing to the devel-
opment of PAH [30]. Previous studies have demonstrated
that inhibition of RASS exerts protective effects on the
development of PAH. For example, de Man et al. [31]
observed that the Ang I type 1 receptor blockers signifi-
cantly reduced RV afterload and pulmonary vascular
remodeling in an experimental model of PAH. Rondelet
et al. [32] also reported preventive effects of losartan in a
shunt-induced PAH model. In this study, we found that
serum Ang II level was significantly increased in the PAH
group compared with the control group, whereas this in-
crease was dramatically attenuated in the PAH þ RSD
RSD prevents the development of PAH 411group. These findings suggest that the protective effects of
RSD on the development of PAH are partly through inhib-
iting the activation of RASS. However, it should be pointed
out that the inhibition of RAAS is not the only one mecha-
nism of RSD to reduce adverse effects. Sympathetic hy-
peractivity has been shown to act as an independent
prognostic indicator in patients with PAH [33]. Previous
studies showed that RSD can significantly inhibit the acti-
vation of sympathetic nervous system. Therefore, RSD may
prevent the development of PAH via suppressing sympa-
thetic activation, which needs to be further investigated.
There are several limitations in this study. First, the
number of animals used was small. Second, two-
dimensional speckle tracking has its own technical limita-
tions; the accuracy of the strain values depends on the
quality of the image and on the frame rates. Third,
although our results indicate that inhibition of RAAS is a
potential mechanism for RSD-medicated protective effects,
the exact mechanism remains unclear. Previous studies
suggest that RSD can inhibit the activation of sympathetic
nerve system [34], which also participates in the develop-
ment of PAH [7]. Therefore, further studies are needed to
determine the effects of RSD on sympathetic tone in the
setting of PAH.
Conclusion
Our findings suggest that RSD prevents the development of
PAH and cardiac dysfunction partly through inhibiting of
RAAS in dogs. Thus, RSD may be a novel therapeutic strat-
egy for the treatment of PAH.Acknowledgments
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